Compare CYTK & ALK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYTK | ALK |
|---|---|---|
| Founded | 1997 | 1932 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Air Freight/Delivery Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.4B |
| IPO Year | 2004 | 2003 |
| Metric | CYTK | ALK |
|---|---|---|
| Price | $64.98 | $39.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 12 |
| Target Price | ★ $88.94 | $64.50 |
| AVG Volume (30 Days) | 1.8M | ★ 5.0M |
| Earning Date | 05-05-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.83 |
| Revenue | $13,368,000.00 | ★ $10,426,000,000.00 |
| Revenue This Year | $6.88 | $10.54 |
| Revenue Next Year | $308.26 | $5.44 |
| P/E Ratio | ★ N/A | $48.06 |
| Revenue Growth | N/A | ★ 8.09 |
| 52 Week Low | $29.31 | $33.03 |
| 52 Week High | $70.98 | $65.35 |
| Indicator | CYTK | ALK |
|---|---|---|
| Relative Strength Index (RSI) | 54.07 | 46.38 |
| Support Level | $59.12 | $37.16 |
| Resistance Level | $67.94 | $40.62 |
| Average True Range (ATR) | 2.25 | 2.02 |
| MACD | 0.26 | 0.79 |
| Stochastic Oscillator | 61.73 | 62.04 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Alaska Air Group Inc operates two airlines, Alaska and Horizon, in three operating segments. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo throughout the U.S., and in parts of Mexico and Costa Rica. The Regional segment includes Horizon's and other third-party carriers' scheduled air transportation for passengers across a shorter distance network within the U.S. and Canada under capacity purchase agreements. The Hawaiian Airlines segment includes scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. It earns revenues from Passenger tickets, including ticket breakage and net of taxes and fees, Passenger ancillary, and Mileage Plan passenger revenue.